

Closed-loop Stimulation:

An Investigational Treatment for Refractory Epilepsy

Chengyuan Wu, MD, MSBmE

Member, International Neuromodulation Society

Thomas Jefferson University Hospital

Department of Neurosurgery, Philadelphia, PA, USA

Epilepsy is characterized by recurrent seizures and is the third most common neurological disorder in the world, with 0.5 - 1% of the population suffering from the disease. (1) In 20 - 40% of these patients, medications alone are unable to adequately control seizures and are therefore diagnosed with drug-resistant epilepsy. (2) For 60% of patients with drug-resistant epilepsy, surgery can significantly reduce or eliminate seizures. (2, 3) Despite such treatments, 15 - 40% of all patients with epilepsy unfortunately continue to have seizures that impair their daily living. (4) In an effort to improve the quality of life for these remaining patients, both epileptologists and neurosurgeons have been turning to the use of neuromodulation – the application of electric currents to the nervous system.

Existing Types of Neuromodulation Used for Epilepsy

Over the past few decades, neuromodulation for epilepsy has grown dramatically. The FDA has approved vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy. Other types of neuromodulation that have been explored include trigeminal nerve stimulation (TNS), deep brain stimulation (DBS), and more recently, closed-loop stimulation. Both DBS and closed-loop systems were under FDA review in 2012 as investigational therapies for epilepsy in the United States. (5)

A closed-loop system only delivers stimulation when it detects the beginnings of a seizure

A Brief History of Closed-Loop Neurostimulation

Unlike VNS and DBS, which administer continuous stimulation, a closed-loop neuromodulation system only delivers stimulation when it detects the beginnings of seizure activity. In that way, it functions much like a pacemaker does to stop abnormal heart rhythms. Such stimulation works to either reduce the risk of having a seizure altogether or stops seizures from spreading to other parts of the brain.

Patients who are evaluated for traditional epilepsy surgery often need to undergo an initial surgical procedure to determine exactly where the seizures start. To do this, patients are monitored for seizures during a hospital stay. Brainwaves are monitored using an electroencephalogram (EEG), which involves placing electrodes on the brain surface, with wires exiting out through the skull and scalp. Once a seizure occurs, doctors can use the EEG to pinpoint the area of the brain that is causing seizures and define the target for surgery.

After promising results were observed in animal testing, closed-loop stimulation was studied in patient volunteers who were undergoing this type of invasive monitoring. (6) At first, a doctor who saw the beginnings of seizure activity on the EEG would initiate a pulse of stimulations. It was seen that in response to that method, abnormal EEG activity could be effectively stopped. (7-9)

In order for a device to function independently, however, reliable seizure detection methods had to be created. In closed-loop stimulation, the first half of the loop is seizure detection, and the second half of the loop is the resulting stimulation. Over the past few decades, seizure detection has matured significantly. Scientists and engineers have developed sophisticated signal processing to more reliably detect the onset of seizures. (10-19)

Studies in the early 2000s showed that closed-loop stimulation provided patients therapeutic benefit with no major side effects. Direct stimulation of the region of the brain suspected to start the seizures (the seizure onset zone) was found to be at least as effective in stopping seizures as indirect stimulation with DBS. (20) Patients not only had fewer seizures, but their remaining seizures were also less severe. (1, 20, 22).

Expected Outcomes with Closed-Loop Stimulation

These early studies laid the foundation for a large clinical trial carried out between 2005 - 2007 across multiple hospitals in the United States. The RNS[®] System Pivotal Clinical Investigation included 191 adult patients with medically refractory epilepsy who were implanted with a closed-loop system at 31 institutions. (22, 23) Patients in the study group had their system turned on for the first 12 weeks, while those in the sham group, to which the study subjects were compared, received no stimulation. During this initial 12-week period, it was noted that patients with an active system averaged 41.5% fewer seizures. At the same time, the sham group only had a 9.4% reduction in the frequency of their seizures. (23) All patients had their system turned on after the initial 12 weeks to see the long-term effects of closed-loop stimulation. After two years, almost half of the participants had at least a 50% reduction in seizure frequency. (22, 24)

Longer-term follow-up shows an increase in the percentage of patients responding to RNS[®] stimulation over time. (22) A 2011 update on these 191 implanted patients gave strong evidence that closed-loop stimulation significantly reduced the frequency of disabling seizures in patients who had previously tried not only anti-seizure medications, but also VNS or traditional epilepsy surgery. (23) With long-term follow-up of an average of six years, patients benefited from approximately a 70% decrease in their seizures. Furthermore, 29% benefited from a seizure-free period of at least six months; with this extending to at least one year in 15% of patients. (43) More important than reductions in seizure frequencies are the significant improvements in

quality of life reported by these patients. (23, 44) Long-term follow-up has also shown that there are no negative effects of chronic stimulation on mood or cognition. (46, 47)

Benefits of a Closed-Loop Stimulation System

Since a closed-loop system provides stimulation only when triggered by early seizure activity, the brain receives less stimulation than it would with earlier types of neuromodulation, which deliver constant stimulation. This reduction in stimulation dose not only helps the battery last longer, but also decreases the potential risk of side effects from long-term continuous stimulation. (25-27) In fact, it has been shown that twice as much stimulation can be safely given with intermittent systems when compared to constant stimulation systems. (26)

Another benefit of closed-loop systems is that stimulation is targeted only at the seizure focus. In all other forms of neuromodulation (VNS, TNS, and DBS), stimulation is applied to seizure-generating circuitry and affects many parts of the brain as well. By isolating the seizure focus, normal parts of the brain are left alone and the chance of side effects is further reduced. (26)

The Device

The first closed-loop stimulation system to be implanted is the responsive neurostimulator system (RNS[®]) by NeuroPace, Inc. (Mountain View, CA), which is currently only available to patients enrolled in clinical trials. (31) It consists of a main component, about the size of a pocket watch (measuring 4 x 6 x 0.7cm) connected to two electrodes. (21)

The main component contains a battery and a computer that can analyze EEG readings and administer stimulation once it detects a seizure onset. This device can also store small snippets of EEG data, which can be downloaded to a NeuroPace computer, which in turn, can transfer the data securely to a central server where the patient's neurologist can see the data.

Two types of electrodes can be used in any combination with this system. One type (a subdural electrode) consists of a strip of four disc-shaped contacts that is placed on the surface of the brain. The other type (a depth electrode) is made up of a strip of cylindrical contacts that is placed into the brain tissue itself. Both types of electrodes are made of a combination of platinum and iridium, which is able to

safely administer therapeutic stimulation without generating a harmful reaction from the surrounding tissue. (3, 22)

Components of the system that are not implanted include a physician programmer, a patient data transmitter used for storing EEG data, and a telemetry wand for wireless transmission of data. (25) These tools allow doctors to transfer the recorded information to a computer for detailed analysis. By doing this, the clinician can see how the device is working, and fine-tune the stimulation programs if necessary. (28)

Being Evaluated for a Closed-Loop Stimulation System

Closed-loop stimulation may be offered to patients 18 years or older who have medically refractory epilepsy and are not candidates for traditional surgery. (23) It also may be offered to patients who have previously undergone traditional epilepsy surgery and continue to suffer from intractable epilepsy. (21, 19) Similarly, patients who had a VNS implanted may also be offered this treatment. (22, 30) For patients to be eligible, the exact location of their particular seizure focus must be known in order to direct stimulation there. (23) A closed-loop system is generally not recommended for epilepsy patients who have more than two distinct seizure foci. While a maximum of four electrodes can be implanted, only two can be connected to the device. (3)

Implantation of a Closed-Loop Stimulation System

Electrodes are only placed in brain areas shown to generate seizures, with the exact placement tailored to each patient. The main component, containing the battery and computer, is designed to be implanted within the skull itself. There are lower rates of infection and hardware failure from this placement compared to traditional systems (like VNS and DBS), in which the battery is implanted under the skin, but over the ribs in the chest. (32)

Implantation of the RNS[®] closed-loop system involves shaving the hair off one side of the head prior to making a fairly large incision in the scalp. Once the skull is exposed, two small holes (about 14mm in diameter) are made for the two electrodes. After the electrodes are in the proper position, covers are placed over the holes to help hold the electrodes in place. The location for implantation of the main component is then determined based on these two holes. A cavity for the main component is drilled out so that the device sits flush with the surface of the skull. The electrodes are connected to the main component and the incision is closed. (3)

Risks Involved

During the RNS[®] System Pivotal Clinical Investigation, the rate of serious complications within the first month of implantation was reported to be 12%, which is comparable to the 15% risk of similar events in patients undergoing invasive monitoring with intracranial electrodes. (23) Common side effects include implant site pain and headache. Less commonly, patients will experience infection, bleeding, or death. (23) Although the complication rate increases to 18.3% over the course of the first 3 months after implantation, this complication rate is favorable in comparison to the overall rate of 36% associated with DBS for Parkinson's disease or essential tremor. (33-37)

At this time, long-term experience beyond five years is currently very limited and the side effects of intermittent, long-term (also termed "chronic") stimulation remain unclear.

Future Directions

A great deal of research remains to be done in closed-loop stimulation for the treatment of epilepsy. Both parts of the closed-loop – seizure detection and stimulation for halting seizures – must not only be individually optimized, but also work in unison with each other.

Seizure Detection versus Seizure Prediction

The earlier stimulation is applied, the more effective it is at stopping abnormal EEG activity. (38) Therefore, both scientists and engineers are working to improve seizure detection, and possibly even predict them. The International Workshop On Seizure Prediction has been held since 2002 to gather and develop new methods. (11, 39)

Current algorithms analyze the EEG signal itself to detect changes that may represent seizure activity. While these systems are very sensitive to abnormalities in the EEG, they will often flag events that are not truly seizures. Therefore, extensive research is being done on signal processing that will help detect reliable changes in EEG signals that may not be otherwise be visible to the naked eye.

The promise of predicting seizures has been supported evidence of changes in EEG activity that occur 7-10 seconds before clinical symptoms. (11) Some researchers have even

reported noticing changes in neuronal activity as early as 7 hours prior to the seizure itself. (15)

Optimization of Stimulation Parameters

Stimulation parameters to halt seizure activity must also be improved. Currently, these parameters are based mainly on experience with DBS and with stimulation performed as part of an evaluation for surgical removal of a seizure focus.

Use as a Long-Term Monitoring Device

As long as the patient continues to download data from the device onto the provided computer, the NeuroPace system has the ability to store EEG data over months and years. This type of long-term monitoring has already proven to be invaluable in our understanding of epilepsy. One study showed that on average it could take over a month before the complete spectrum of a patient's seizure activity was seen. (45) Another demonstrated differences in the time of day that seizures from different parts of the brain occur. (48) A third study has also highlighted the negative effects of caffeine intake on EEG activity. (49) Overall, chronic monitoring with this device provides data in a naturalistic setting, which may be used to help epilepsy treatment teams with treatment decisions.

Technical Advances

The rise of new technologies will only improve our ability to create a more effective closed-loop neurostimulator. Improved wireless transmission of high quality data would significantly reduce the amount of hardware that needs to be implanted. This innovation would allow future versions of such neurostimulators to keep the larger elements of the device in a module to wear on a belt or a vest. (40)

Future applications of closed-loop systems may also be able to track the levels of certain chemicals in the brain. This information could be used independently or along with EEG data in predicting brain states consistent with activity prior to or during a seizure. (40)

The examples above are only a sample of the possibilities that exist for closed-loop neurostimulator systems. In all aspects of neuromodulation, continued collaboration between engineers and doctors will help to advance the field – and ultimately provide higher levels of care for patients.

Please note: *This information should not be used as a substitute for medical treatment and advice. Always consult a medical professional about any health-related questions or concerns.*

For further information see:

WIKISTIM at <http://www.wikistim.org> – This free-to-use collaborative, searchable wiki of published primary neuromodulation therapy research was created in 2013 as a resource for the global neuromodulation community to extend the utility of published clinical research. The goals of WIKISTIM are to improve patient care and the quality of research reports, foster education and communication, reveal research needs, and support the practice of evidence-based medicine.

References

1. Choi H, Sell RL, Lenert L, et al. Epilepsy surgery for pharmaco-resistant temporal lobe epilepsy: a decision analysis. *JAMA : the journal of the American Medical Association*. 2008;300(21):2497–505. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19050193>. Accessed October 3, 2012.
2. COOKE PM, SNIDER RS. Some cerebellar influences on electrically-induced cerebral seizures. *Epilepsia*. 1955;4:19–28. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/13305547>. Accessed October 3, 2012.
3. Sharan AD, Rezai AR. Neurostimulation for Epilepsy. In: Krames ES, Peckham HP, Rezai AR, eds. *Neuromodulation*. London: Elsevier; 2009:617–66.
4. Vonck K, Boon P, Achten E, De Reuck J, Caemaert J. Long-term amygdalohippocampal stimulation for refractory temporal lobe epilepsy. *Annals of neurology*. 2002;52(5):556–65. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12402252>. Accessed October 3, 2012.
5. Health C for D and R. Recently-Approved Devices - VNS Therapy System - P9700035050. Available at: <http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm078532.htm>. Accessed October 3, 2012.
6. Good LB, Sabesan S, Marsh ST, et al. Control of synchronization of brain dynamics leads to control of epileptic seizures in rodents. *International journal of neural systems*. 2009;19(3):173–96. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3120842&tool=pmcentrez&rendertype=abstract>. Accessed October 3, 2012.
7. Kossoff EH, Ritzl EK, Politsky JM, et al. Effect of an external responsive neurostimulator on seizures and electrographic discharges during subdural electrode monitoring. *Epilepsia*. 2004;45(12):1560–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15571514>. Accessed October 3, 2012.
8. Lesser RP, Kim SH, Beyderman L, et al. Brief bursts of pulse stimulation terminate after discharges caused by cortical stimulation. *Neurology*. 1999;53(9):2073–81. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10599784>. Accessed October 4, 2012.
9. Al-Otaibi FA, Hamani C, Lozano AM. Neuromodulation in

- epilepsy. *Neurosurgery*. 2011;69(4):957–79; discussion 979. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21716154>. Accessed October 4, 2012.
10. Davis R, Emmonds SE. Cerebellar stimulation for seizure control: 17-year study. *Stereotactic and functional neurosurgery*. 1992;58(1-4):200–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1439341>. Accessed October 4, 2012.
11. Litt B, Echaz J. Prediction of epileptic seizures. *Lancet neurology*. 2002;1(1):22–30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12849542>. Accessed October 3, 2012.
12. Mormann F, Elger CE, Lehnertz K. Seizure anticipation: from algorithms to clinical practice. *Current opinion in neurology*. 2006;19(2):187–93. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16538095>. Accessed October 3, 2012.
13. Esteller R, Echaz J, Tcheng T, Litt B, Pless B. Line length: an efficient feature for seizure onset detection. In: *2001 Conference Proceedings of the 23rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society*. Vol 2. IEEE; 2001:1707–1710. Available at: <http://ieeexplore.ieee.org/articleDetails.jsp?arnumber=1020545&contentType=Conference+Publications>. Accessed October 3, 2012.
14. D’Alessandro M, Esteller R, Vachtsevanos G, et al. Epileptic seizure prediction using hybrid feature selection over multiple intracranial EEG electrode contacts: a report of four patients. *IEEE transactions on bio-medical engineering*. 2003;50(5):603–15. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12769436>. Accessed October 3, 2012.
15. Litt B, Esteller R, Echaz J, et al. Epileptic seizures may begin hours in advance of clinical onset: a report of five patients. *Neuron*. 2001;30(1):51–64. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11343644>. Accessed October 3, 2012.
16. Echaz J, Padovani DA, Esteller R, Litt B, Vachtsevanos G. Median-based filtering methods for EEG seizure detection. In: *Proceedings of the First Joint BMES/EMBS Conference. 1999 IEEE Engineering in Medicine and Biology 21st Annual Conference and the 1999 Annual Fall Meeting of the Biomedical Engineering Society (Cat. No. 99CH37015)*. Vol 1. IEEE; 1999:439. Available at: <http://ieeexplore.ieee.org/articleDetails.jsp?arnumber=802517&contentType=Conference+Publications>. Accessed October 3, 2012.
17. Gotman J. Automatic seizure detection: improvements and evaluation. *Electroencephalography and clinical neurophysiology*. 1990;76(4):317–24. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1699724>. Accessed October 3, 2012.
18. Viglione SS, Walsh GO. Proceedings: Epileptic seizure prediction. *Electroencephalography and clinical neurophysiology*. 1975;39(4):435–6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/51767>. Accessed October 4, 2012.
19. Osorio I, Frei MG, Wilkinson SB. Real-time automated detection and quantitative analysis of seizures and short-term prediction of clinical onset. *Epilepsia*. 1998;39(6):615–27. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9637604>. Accessed October 4, 2012.
20. Osorio I, Frei MG, Sunderam S, et al. Automated seizure abatement in humans using electrical stimulation. *Annals of neurology*. 2005;57(2):258–68. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15668970>. Accessed October 4, 2012.
21. Anderson WS, Kossoff EH, Bergey GK, Jallo GI. Implantation of a responsive neurostimulator device in patients with refractory epilepsy. *Neurosurgical focus*. 2008;25(3):E12. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18759613>. Accessed October 3, 2012.
22. Gigante PR, Goodman RR. Alternative surgical approaches in epilepsy. *Current neurology and neuroscience reports*. 2011;11(4):404–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21584657>. Accessed October 3, 2012.
23. Morrell MJ. Responsive cortical stimulation for the treatment of medically intractable partial epilepsy. *Neurology*. 2011;77(13):1295–304. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21917777>.
24. Anon. Pivotal Trial Data Demonstrate NeuroPace RNS® System Reduced Seizures in People with Epilepsy. *NeuroPace: News*.
25. Sun FT, Morrell MJ, Wharen RE. Responsive cortical stimulation for the treatment of epilepsy. *Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics*. 2008;5(1):68–74. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18164485>. Accessed October 3, 2012.
26. Morrell M. Brain stimulation for epilepsy: can scheduled or responsive neurostimulation stop seizures? *Current opinion in neurology*. 2006;19(2):164–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16538091>. Accessed October 3, 2012.
27. Springer US, Bowers D, Goodman WK, et al. Long-term habituation of the smile response with deep brain stimulation. *Neurocase*. 2006;12(3):191–6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16801154>. Accessed October 4, 2012.
28. Jobst BC. Electrical stimulation in epilepsy: vagus nerve and brain stimulation. *Current treatment options in neurology*. 2010;12(5):443–53. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20842599>. Accessed October 4, 2012.
29. Smith JR, Fountas KN, Murro AM, et al. Closed-loop stimulation in the control of focal epilepsy of insular origin. *Stereotactic and functional neurosurgery*. 2010;88(5):281–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20588079>. Accessed October 4, 2012.
30. Zhong X-L, Yu J-T, Zhang Q, Wang N-D, Tan L. Deep brain stimulation for epilepsy in clinical practice and in animal models. *Brain research bulletin*. 2011;85(3-4):81–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21457763>. Accessed October 4, 2012.
31. Anon. NeuroPace submits PMA application for FDA approval of novel investigational device for epilepsy. *NeuroPace: News*. Available at: <http://www.neuropace.com/about/news/20100708.html>. Accessed July 8, 2010.
32. Andrews RJ. Neuromodulation: advances in the next five years. *Annals of the New York Academy of Sciences*. 2010;1199:204–11. Available at:

- <http://www.ncbi.nlm.nih.gov/pubmed/20633126>. Accessed October 4, 2012.
33. Hariz MI. Complications of deep brain stimulation surgery. *Movement disorders : official journal of the Movement Disorder Society*. 2002;17 Suppl 3:S162-6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11948772>. Accessed October 3, 2012.
34. Joint C, Nandi D, Parkin S, Gregory R, Aziz T. Hardware-related problems of deep brain stimulation. *Movement disorders : official journal of the Movement Disorder Society*. 2002;17 Suppl 3:S175-80. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11948774>. Accessed October 3, 2012.
35. Beric A, Kelly P, Rezai A, et al. Complications of deep brain stimulation surgery. *Stereotactic and functional neurosurgery*. 2001;77(1-4):73-8.
36. Oh MY, Abosch A, Kim SH, Lang AE, Lozano AM. Long-term hardware-related complications of deep brain stimulation. *Neurosurgery*. 2002;50(6):1268-74; discussion 1274-6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12015845>. Accessed October 4, 2012.
37. Koller WC, Lyons KE, Wilkinson SB, Troster AI, Pahwa R. Long-term safety and efficacy of unilateral deep brain stimulation of the thalamus in essential tremor. *Movement disorders : official journal of the Movement Disorder Society*. 2001;16(3):464-8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11391740>. Accessed October 4, 2012.
38. Motamedi GK, Lesser RP, Miglioretti DL, et al. Optimizing parameters for terminating cortical afterdischarges with pulse stimulation. *Epilepsia*. 2002;43(8):836-46. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12181002>.
39. Lehnertz K, Litt B. The First International Collaborative Workshop on Seizure Prediction: summary and data description. *Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology*. 2005;116(3):493-505. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15721063>. Accessed October 3, 2012.
40. Shah RS, Chang S-Y, Min H-K, et al. Deep brain stimulation: technology at the cutting edge. *Journal of clinical neurology (Seoul, Korea)*. 2010;6(4):167-82. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3024521&tool=pmcentrez&rendertype=abstract>. Accessed October 4, 2012.
41. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. *JAMA*. 2009;301(1):63-73.
42. Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2010 Mar 16;74(11):924-31.
43. Geller EB, Skarpaas TL, Gross RE, Goodman RR, Barkley GL, Bazil CW, Berg MJ, Bergey GK, Cash SS, Cole AJ, Duckrow RB, Edwards JC, Eisenschenk S, Fessler J, Fountain NB, Goldman AM, Gwinn RP, Heck C, Herekar A, Hirsch LJ, Jobst BC, King-Stephens D, Labar DR, Leiphart JW, Marsh WR, Meador KJ, Mizrahi EM, Murro AM, Nair DR, Noe KH, Park YD, Rutecki PA, Salanova V, Sheth RD, Shields DC, Skidmore C, Smith MC, Spencer DC, Srinivasan S, Tatum W, Van Ness PC, Vossler DG, Wharen RE Jr, Worrell GA, Yoshor D, Zimmerman RS, Cicora K, Sun FT, Morrell MJ. Brain-responsive neurostimulation in patients with medically intractable mesial temporal lobe epilepsy. *Epilepsia*. 2017 Jun;58(6):994-1004.
44. Meador KJ, Kapur R, Loring DW, Kanner AM, Morrell MJ; RNS® System Pivotal Trial Investigators. Quality of life and mood in patients with medically intractable epilepsy treated with targeted responsive neurostimulation. *Epilepsy Behav*. 2015 Apr;45:242-7.
45. King-Stephens D, Mirro E, Weber PB, Laxer KD, Van Ness PC, Salanova V, Spencer DC, Heck CN, Goldman A, Jobst B, Shields DC, Bergey GK, Eisenschenk S, Worrell GA, Rossi MA, Gross RE, Cole AJ, Sperling MR, Nair DR, Gwinn RP, Park YD, Rutecki PA, Fountain NB, Wharen RE, Hirsch LJ, Miller IO, Barkley GL, Edwards JC, Geller EB, Berg MJ, Sadler TL, Sun FT, Morrell MJ. Lateralization of mesial temporal lobe epilepsy with chronic ambulatory electrocorticography. *Epilepsia*. 2015 Jun;56(6):959-67.
46. Loring DW, Kapur R, Meador KJ, Morrell MJ. Differential neuropsychological outcomes following targeted responsive neurostimulation for partial-onset epilepsy. *Epilepsia*. 2015 Nov;56(11):1836-44.
47. Spencer D. Responsive Neurostimulation and Cognition. *Epilepsy Curr*. 2016 Mar-Apr;16(2):98-100.
48. Spencer DC, Sun FT, Brown SN, Jobst BC, Fountain NB, Wong VS, Mirro EA, Quigg M. Circadian and ultradian patterns of epileptiform discharges differ by seizure-onset location during long-term ambulatory intracranial monitoring. *Epilepsia*. 2016 Sep;57(9):1495-502.
49. Mackow MJ, Krishnan B, Bingaman WE, Najm IM, Alexopoulos AV, Nair DR. Increased caffeine intake leads to worsening of electrocorticographic epileptiform discharges as recorded with a responsive neurostimulation device. *Clin Neurophysiol*. 2016 Jun;127(6):2341-2.